Drugs / 162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06159062 | Jun → Jul 2024 | chronic hepatitis B virus infection | Yangshengtang Co., Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06159062 ↗ |
| Modality | Monoclonal antibody | “The investigational product 162 is a novel monoclonal antibody targeting HBsAg.” NCT06159062 ↗ |